

**HSBC Global Investment Funds**

# GLOBAL EQUITY SUSTAINABLE HEALTHCARE

Monthly report 29 February 2024 | Share class AC



## Investment objective

The Fund aims to provide long term capital growth and income by investing in a portfolio of shares of companies that may benefit from increasingly constrained healthcare budgets anywhere in the world, while promoting ESG characteristics. The Fund qualifies under Article 8 of SFDR.



## Investment strategy

The Fund is actively managed. In normal market conditions, the Fund will invest at least 70% of its assets in shares (or securities similar to shares) of Sustainable Healthcare Companies of any size, that are based in, or carry out the larger part of their business activities in developed and emerging markets. The Fund will not invest in shares of companies which have material exposure, exceeding a revenue exposure threshold, to specific Excluded Activities that will not be higher than 30% of the relevant company's total revenue. The Fund can invest up to 40% in China A and China B-shares. For China A-shares, up to 20% through the Shanghai-Hong Kong Stock Connect and/or the Shenzhen-Hong Kong Stock Connect, and up to 20% in CAAPs. The Fund may invest in money market instruments and up to 10% of its assets in other funds, including HSBC funds. See the Prospectus for a full description of the investment objectives and derivative usage.



## Main risks

- The Fund's unit value can go up as well as down, and any capital invested in the Fund may be at risk.
- The value of investible securities can change over time due to a wide variety of factors, including but not limited to: political and economic news, government policy, changes in demographics, cultures and populations, natural or human-caused disasters etc.
- The Fund may be concentrated in a limited number of securities, economic sectors and/or countries and as a result, may be more volatile and have a greater risk of loss than more broadly diversified funds.

## Share Class Details

### Key metrics

NAV per Share	<b>USD 10.29</b>
Performance 1 month	<b>4.10%</b>

### Fund facts

UCITS V compliant	<b>Yes</b>
Dividend treatment	<b>Accumulating</b>
Dealing frequency	<b>Daily</b>
Valuation Time	<b>17:00 Luxembourg</b>
Share Class Base Currency	<b>USD</b>
Domicile	<b>Luxembourg</b>
Inception date	<b>28 July 2021</b>
Fund Size	<b>USD 265,702,520</b>
Reference benchmark	<b>100% MSCI World Health Care Index (USD)</b>
Managers	<b>Michael Schroter Nathalie Flury</b>

### Fees and expenses


Minimum Initial Investment	<b>USD 5,000</b>
Ongoing Charge Figure <sup>1</sup>	<b>1.850%</b>
Management fee	<b>1.500%</b>

### Codes

ISIN	<b>LU2324357040</b>
Bloomberg ticker	<b>HSESHAU LX</b>

<sup>1</sup>Ongoing Charges Figure is based on expenses over a year. The figure includes annual management charge but not the transaction costs. Such figures may vary from time to time.

Performance




Performance (%)	YTD	1 month	3 months	6 months	1 year	3 years ann	5 years ann	Since inception ann
AC	9.14	4.10	15.25	12.13	17.54	--	--	-2.53
Reference benchmark	5.00	2.25	9.64	7.55	14.32	--	--	3.22


Rolling Performance (%)	28/02/23-29/02/24	28/02/22-28/02/23	28/02/21-28/02/22	29/02/20-28/02/21	28/02/19-29/02/20
AC	17.54	-5.20	--	--	--
Reference benchmark	14.32	-2.23	--	--	--

Equity characteristics	Fund	Reference benchmark	3-Year Risk Measures	AC	Reference benchmark
No. of holdings ex cash	41	135	Volatility	--	--
Average Market Cap (USD Mil)	146,885	227,634	Information ratio	--	--
			Beta	--	--

Sector Allocation (%)



Geographical Allocation (%)



Top 10 Holdings	Sector	Weight (%)
ELI LILLY & CO	Pharmaceuticals	6.39
NOVO NORDISK A/S-B	Pharmaceuticals	4.93
UNITEDHEALTH GROUP INC	Health Care Providers and Services	4.42
TENET HEALTHCARE CORP	Health Care Providers and Services	4.05
MCKESSON CORP	Health Care Providers and Services	3.86
MERCK & CO. INC.	Pharmaceuticals	3.81
VERTEX PHARMACEUTICALS INC	Biotechnology	3.74
BOSTON SCIENTIFIC CORP	Health Care Equipment and Supplies	3.42
NEUROCRINE BIOSCIENCES INC	Biotechnology	3.06
REGENERON PHARMACEUTICALS	Biotechnology	3.00

## Monthly performance commentary

At country level, stock selection was positive for the month. Positive performance came from USA and Switzerland, though this was offset by negative stock selection in the UK and France.

USA Health Care security, ARCUTIS BIOTHERAPEUTICS INC with total effect 0.84% was the top contributor. Additionally, USA Health Care security, R1 RCM INC was the second largest contributor with total effect 0.42%. USA Health Care security, ESTABLISHMENT LABS HOLDINGS also contributed with total effect 0.38%.

On the other side, detractors included USA Health Care security INSPIRE MEDICAL SYSTEMS INC with total effect -0.35%, USA Health Care holding, NEUROCRINE BIOSCIENCES INC with total effect -0.31%, and USA Health Care holding, INSULET CORP with total effect -0.25%.

During this period, we opened positions in MERCK & CO. INC and NATERA INC. On the other hand we closed positions in CENTENE CORP.

Country allocation effects are residual to stock selection. At a country level, effects were positive, given an underweight exposure to Switzerland.

## Risk Disclosure

- Investment Leverage occurs when the economic exposure is greater than the amount invested, such as when derivatives are used. A Fund that employs leverage may experience greater gains and/or losses due to the amplification effect from a movement in the price of the reference source.
- Where overseas investments are held the rate of currency exchange may cause the value of such investments to go down as well as up.
- Further information on the potential risks can be found in the Key Investor Information Document (KID) and/or the Prospectus or Offering Memorandum.

## Index Disclaimer


Source: MSCI. The MSCI information may only be used for your internal use, may not be reproduced or disseminated in any form and may not be used as a basis for or a component of any financial instruments or products or indices. None of the MSCI information is intended to constitute investment advice or a recommendation to make (or refrain from making) any kind of investment decision and may not be relied on as such. Historical data and analysis should not be taken as an indication or guarantee of any future performance analysis, forecast or prediction. The MSCI information is provided on an “as is” basis and the user of this information assumes the entire risk of any use made of this information. MSCI, each of its affiliates and each other person involved in or related to compiling, computing or creating any MSCI information (collectively, the “MSCI Parties”) expressly disclaims all warranties (including, without limitation, any warranties of originality, accuracy, completeness, timeliness, non-infringement, merchantability and fitness for a particular purpose) with respect to this information. Without limiting any of the foregoing, in no event shall any MSCI Party have any liability for any direct, indirect, special, incidental, punitive, consequential (including, without limitation, lost profits) or any other damages. (www.msci.com)

## Important Information

HSBC Global Asset Management (Bermuda) Limited (“AMBM”) of 37 Front Street, Hamilton, Bermuda, is a wholly owned subsidiary of HSBC Bank Bermuda Limited (the “Bank”). AMBM and the Bank are licensed to conduct investment business by the Bermuda Monetary Authority. Funds managed by AMBM are offered by Prospectus only in those jurisdictions where they are permitted by law. Persons are required to inform themselves and observe any relevant restrictions. AMBM makes no representation as to the suitability of the funds for investors. Investors should be aware that performance returns are affected by market fluctuations. Investing entails risks, including possible loss of principal. Past performance is no guarantee of future performance. Investors should note that the use of derivatives and investments involving a currency other than their own will create foreign exchange exposure, which involves special risks. It is the aim of the Company to preserve capital and, where applicable, to maintain a stable net asset value per share; these aims are not guaranteed. Additionally, investors should consider their investment objectives, whether or not they can assume these risks and should undertake their own appropriate professional advice. Expressions of opinion contained herein are subject to change without notice. For investors investing via a nominee service provider, the nominee service provider will process the transaction and route all settlement proceeds to you, which may extend the settlement period. Please contact your investment advisor/ introducing agent, or in the absence of those the nominee provider directly, to confirm the settlement period. Issued by HSBC Global Asset Management (Bermuda) Limited Licensed to conduct investment business by the Bermuda Monetary Authority © Copyright HSBC Global Asset Management (Bermuda) Limited 2022. All Rights Reserved. Further information can be found in the prospectus.

**Source: HSBC Asset Management, data as at 29 February 2024**

Follow us on:



HSBC Asset Management (Bermuda)  
Limited Telephone: +441 299 6644  
Email: [asset.management@hsbc.bm](mailto:asset.management@hsbc.bm)  
Website: [assetmanagement.hsbc.bm](http://assetmanagement.hsbc.bm)

---

### Glossary

